Purple Biotech Ltd (PPBT)

Purple Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cost of Revenue	0.2	0.2	0.12	0.06	0.06	0.08
Gross Profit	-0.2	-0.2	-0.12	-0.06	-0.06	-0.08
Selling, General & Admin	3.83	5.04	6.03	6.04	5.9	3.96
Research & Development	15.65	17.03	16.32	11.83	7.24	2.28
Operating Expenses	19.47	22.08	22.35	17.87	13.14	6.24
Operating Income	-19.67	-22.27	-22.47	-17.92	-13.2	-6.32
Interest & Investment Income	0.52	0.47	0.53	0.32	0.25	0.15
Currency Exchange Gain (Loss)	-0.01	-0.01	0.06	-0.13	-0.01	-0.1
Other Non Operating Income (Expenses)	3.25	1.83	0.25	-0.08	-15.71	1.43
EBT Excluding Unusual Items	-15.91	-19.98	-21.63	-17.81	-28.66	-4.84
Legal Settlements	-	-	-0.14	-0.01	-0.04	-0.36
Pretax Income	-16.11	-19.98	-21.76	-17.83	-28.7	-5.19
Income Tax Expense	-	-	-	-	-	0.22
Earnings From Continuing Operations	-16.11	-19.98	-21.76	-17.83	-28.7	-5.41
Earnings From Discontinued Operations	-	-	-	-0.64	0.63	-0.49
Net Income to Company	-16.11	-19.98	-21.76	-18.47	-28.07	-5.89
Minority Interest in Earnings	0.08	0.1	0.09	0.08	0.08	0.04
Net Income	-16.03	-19.88	-21.67	-18.38	-28	-5.85
Net Income to Common	-16.03	-19.88	-21.67	-18.38	-28	-5.85
Shares Outstanding (Basic)	253	221	181	176	115	19
Shares Outstanding (Diluted)	253	221	181	176	115	19
Shares Change (YoY)	30.82%	22.41%	2.92%	52.76%	493.78%	36.34%
EPS (Basic)	-0.06	-0.09	-0.12	-0.10	-0.24	-0.30
EPS (Diluted)	-0.06	-0.09	-0.12	-0.10	-0.24	-0.30
Free Cash Flow	-17.7	-19.93	-16.76	-15.37	-12.25	-5.59
Free Cash Flow Per Share	-0.07	-0.09	-0.09	-0.09	-0.11	-0.29
EBITDA	-19.62	-22.23	-22.42	-17.69	-12.96	-6.14
D&A For EBITDA	0.04	0.05	0.05	0.23	0.24	0.18
EBIT	-19.67	-22.27	-22.47	-17.92	-13.2	-6.32

Source: S&P Capital IQ. Standard template. Financial Sources.